Page results
-
More than 800 patients on waiting lists for Ear, Nose and Throat appointments across North Central London seen in two days during ENT surgery ‘super-weekend’
-
A front page story and patient case study highlight SUMMIT Study early diagnosis outcomes.
-
Young cancer patients and staff couldn’t believe their eyes when David Beckham paid a visit to the University College Hospital Macmillan Cancer Centre earlier this year.
-
In a major study involving UCLH a third of people who took a new drug for treating obesity lost more than one-fifth of their total body weight.
-
Our Getting Ready for Transition (GReaT) to secondary school parent information session will run on Tuesday 31 January 2023.
-
The world’s first COVID-19 vaccine study researching alternating doses and intervals of approved vaccines is taking place at UCLH.
-
UCLH has recruited the first European participant to a trial looking at treating non-hospitalised Covid-19 patients with the drug remdesivir.
-
This page provides information about the WEB device and how it is used to treat cerebral (brain) aneurysms
-
Our outpatient clinics will remain predominantly virtual throughout the COVID-19 pandemic. Please continue to refer via the NHS e-referral service.
-
All GPs are now welcome to use our national Infectious & Tropical Disease Advice and Guidance function on the e-referral system (NHS e-RS)
File results
-
FOI/2024/0518 - Post partum balloons buying/ usage numbers
-
FOI/2024/0520 - Treatment of melanoma
-
FOI/2024/05523 - Dabrafenib + Trametinib cancer treatment for metastatic and adjuvant melanoma/ lung/ colorectal cancer
-
FOI/2024/0527 - Treatment for renal cell carcinoma
-
FOI/2024/0528 - Open MRIs referrals for patient size/ spend on specialist bariatric equipment 2017-2024
-
FOI/2024/0529 - Medical Associate Professionals (MAPs) at Trust
-
FOI/2024/0530 - Radiology/ imaging examinations/ patient access to radiology images
-
FOI/2024/0532 - Patient treatment/ care/ consent
-
FOI/2024/0543 - Guidelines, policies for the treatment of obesity/ pathways for Tier 3 or Tier 4 weight management services
-
FOI/2024/0356 - Treatment with Durvalumab and Nivolumab for biliary tract/ non-small cell lung cancer